Malavasi F - Search Results

1

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.

Palladini G, Milani P, Malavasi F, Merlini G. Palladini G, et al. Among authors: malavasi f. Cells. 2021 Mar 4;10(3):545. doi: 10.3390/cells10030545. Cells. 2021. PMID: 33806310 Free PMC article. Review.

2

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.

Zannetti BA, Faini AC, Massari E, Geuna M, Maffini E, Poletti G, Cerchione C, Martinelli G, Malavasi F, Lanza F. Zannetti BA, et al. Among authors: malavasi f. Cells. 2020 Dec 11;9(12):2666. doi: 10.3390/cells9122666. Cells. 2020. PMID: 33322499 Free PMC article. Review.

3

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.

Roccatello D, Fenoglio R, Sciascia S, Naretto C, Rossi D, Ferro M, Barreca A, Malavasi F, Baldovino S. Roccatello D, et al. Among authors: malavasi f. Int J Mol Sci. 2020 Jun 10;21(11):4129. doi: 10.3390/ijms21114129. Int J Mol Sci. 2020. PMID: 32531894 Free PMC article. Review.

4

CD14⁺ CD16⁺ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy.

Storti P, Vescovini R, Costa F, Marchica V, Toscani D, Dalla Palma B, Craviotto L, Malavasi F, Giuliani N. Storti P, et al. Among authors: malavasi f. Br J Haematol. 2020 Aug;190(3):430-436. doi: 10.1111/bjh.16548. Epub 2020 Mar 12. Br J Haematol. 2020. PMID: 32162328 Free article.

5

CD38 antibodies in multiple myeloma: back to the future.

van de Donk NWCJ, Richardson PG, Malavasi F. van de Donk NWCJ, et al. Among authors: malavasi f. Blood. 2018 Jan 4;131(1):13-29. doi: 10.1182/blood-2017-06-740944. Epub 2017 Nov 8. Blood. 2018. PMID: 29118010 Free article. Review.

6

Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.

Chillemi A, Zaccarello G, Quarona V, Ferracin M, Ghimenti C, Massaia M, Horenstein AL, Malavasi F. Chillemi A, et al. Among authors: malavasi f. Mol Med. 2013 May 20;19(1):99-108. doi: 10.2119/molmed.2013.00009. Mol Med. 2013. PMID: 23615966 Free PMC article. Review.

7

[No title available]

[No authors listed] [No authors listed] PMID: 36164165

8

NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model.

Horenstein AL, Chillemi A, Quarona V, Zito A, Roato I, Morandi F, Marimpietri D, Bolzoni M, Toscani D, Oldham RJ, Cuccioloni M, Sasser AK, Pistoia V, Giuliani N, Malavasi F. Horenstein AL, et al. Among authors: malavasi f. Cells. 2015 Sep 17;4(3):520-37. doi: 10.3390/cells4030520. Cells. 2015. PMID: 26393653 Free PMC article. Review.

9

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma.

Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V, Malavasi F. Morandi F, et al. Among authors: malavasi f. Front Immunol. 2018 Nov 28;9:2722. doi: 10.3389/fimmu.2018.02722. eCollection 2018. Front Immunol. 2018. PMID: 30546360 Free PMC article. Review.

10

Editorial: Immunotherapy in Multiple Myeloma.

Giuliani N, Malavasi F. Giuliani N, et al. Among authors: malavasi f. Front Immunol. 2019 Aug 14;10:1945. doi: 10.3389/fimmu.2019.01945. eCollection 2019. Front Immunol. 2019. PMID: 31475006 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

347 results

Search Page